Table 2. Detailed patient characteristics and CTC results.
| Status at first diagnoses | Current status at blood withdrawal | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | T | N | M | Liver | Lung | Lymphnode | Bone | AdnaTest® (transcripts) | CellSearch® (CTC count) | CTCs positive for EGFR (CellSearch®) | Line of treatment | Remission status |
| 1 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 0 | 5 | PD |
| 2 | 4 | 2 | 0 | 1 | 1 | 0 | 0 | EpCAM/CEA | 1 | 0 | 5 | SD |
| 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | EpCAM/CEA | 0 | 0 | 1 | SD |
| 4 | - | - | - | 0 | 0 | 0 | 0 | EpCAM | 1 | 0 | 4 | SD |
| 5 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 4 | SD |
| 6 | 4 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | - | - | 2 | SD |
| 7 | - | - | - | 1 | 0 | 1 | 0 | 0 | - | - | 2 | SD |
| 8 | - | - | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 0 | 5 | PD |
| 9 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 4 | SD |
| 10 | - | - | 1 | 1 | 0 | 0 | 0 | CEA | 0 | 0 | 3 | PD |
| 11 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | PD |
| 12 | 3 | 0 | 0 | 1 | 0 | 0 | 0 | EpCAM/CEA | 8 | 2 | 7 | PD |
| 13 | - | - | - | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | PD |
| 14 | - | - | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | SD |
| 15 | - | - | 1 | 1 | 1 | 0 | 0 | CEA | 4 | 0 | 3 | SD |
| 16 | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - |
| 17 | 4 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 4 | SD |
| 18 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 10 | 3 | 5 | PD |
| 19 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | CEA | - | - | 5 | SD |
| 20 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 5 | SD |
| 21 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | EpCAM | 5 | 3 | 8 | SD |
| 22 | 3 | 1 | 0 | 1 | 0 | 0 | 0 | - | 0 | 0 | 2 | - |
| 23 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | SD |
| 24 | 3 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | - |
| 25 | 2 | 2 | - | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | PD |
| 26 | 3 | 0 | - | 1 | 0 | 1 | 0 | - | 1 | 0 | 3 | PD |
| 27 | - | - | 1 | 1 | 1 | 0 | 0 | 0 | - | - | 2 | PD |
| 28 | 4 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | PD |
| 29 | - | - | 1 | 1 | 1 | 0 | 1 | 0 | - | - | 3 | PD |
| 30 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 12 | 0 | 3 | PD |
| 31 | - | - | 1 | 1 | 0 | 0 | 0 | - | 3 | 1 | - | PD |
| 32 | - | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 7 | 0 | 1 | SD |
| 33 | 3 | 1 | 0 | 0 | 1 | 0 | 0 | CEA | 1 | 0 | 4 | SD |
| 34 | 3 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 6 | SD |
| 35 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 3 | 2 | 3 | SD |
| 36 | 4 | 1 | 0 | 1 | 1 | 0 | 0 | EpCAM | 0 | 0 | 2 | SD |
| 37 | 4 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | PD |
| 38 | - | - | - | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | PD |
| 39 | 3 | 2 | 0 | 1 | 1 | 0 | 0 | CEA | 2 | 0 | 7 | RM |
| 40 | 4 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 5 | PD |
| 41 | - | - | 1 | 1 | 1 | 0 | 0 | EpCAM | 3 | 2 | 6 | PD |
| 42 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | EpCAM/CEA/EGFR | 44 | 0 | 1 | PD |
| 43 | 3 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | SD |
| 44 | - | - | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | SD |
| 45 | - | - | - | 0 | 1 | 1 | 1 | 0 | 4 | 0 | 6 | - |
| 46 | 4 | 0 | 0 | 1 | 1 | 0 | 0 | - | 3 | 0 | - | SD |
| 47 | 3 | 1 | 1 | 1 | 0 | 1 | 0 | - | 0 | 0 | 6 | - |
Table 2 discloses detailed patient characteristics of 47 metastatic colorectal cancer patients and their corresponding CTC results (AdnaTest® or CellSearch®). Remission status after blood withdrawal is indicated as stable disease (SD), progressive disease (PD), or remission (RM). Missing data points are indicated as (-).